La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster Review - Neuroprotective agent

Terms

6Review
5Neuroprotective agent
4In vitro
3Selectivity
2Structure activity relation
2Pituitary adenylate cyclase activating peptide
2Mechanism of action
2In vivo

Associations

Freq.WeightAssociation
44In vitro - Neuroprotective agent
33Neuroprotective agent - Review
22Neuroprotective agent - Structure activity relation
22Selectivity - Structure activity relation
22Pituitary adenylate cyclase activating peptide - Structure activity relation
22Pituitary adenylate cyclase activating peptide - Selectivity
22Neuroprotective agent - Selectivity
22Neuroprotective agent - Pituitary adenylate cyclase activating peptide
22Mechanism of action - Review
22Mechanism of action - Neuroprotective agent
22In vivo - Review
22In vivo - Neuroprotective agent
22In vivo - Mechanism of action
22In vitro - Structure activity relation
22In vitro - Selectivity
22In vitro - Review
22In vitro - Pituitary adenylate cyclase activating peptide
22In vitro - Mechanism of action
22In vitro - In vivo

Documents par ordre de pertinence
000208 (2009) S. Bourgault [Canada, France] ; D. Vaudry [France] ; A. Dejda [Canada, France] ; N. D. Doan [Canada, France] ; H. Vaudry [France] ; A. Fournier [Canada, France]Pituitary Adenylate Cyclase-Activating Polypeptide: Focus on Structure-Activity Relationships of a Neuroprotective Peptide
000173 (2011) Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada]Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects
000304 (2000) M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada]Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS
000087 (2014) Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France]Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients
000285 (2002) Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France]Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture
000239 (2007) M. Berk [Australie] ; S. Dodd [Australie] ; M. Kauer-Sant'Anna [Canada] ; G. S. Malhi [Australie] ; M. Bourin [France] ; F. Kapczinski [Brésil] ; T. Norman [Australie]Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder
000268 (2004) M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada]Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate
000277 (2003) Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada]Presymptomatic compensation in Parkinson's disease is not dopamine-mediated
000325 (1997) A. Destee [France]Données séméiologiques et principes actuels du traitement médical

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022